Clinical efficacy of intravenous calcium-sensing receptor agonist (etelcalcetide hydrochloride) for secondary hyperparathyroidism

Clinical efficacy of intravenous calcium-sensing receptor agonist (etelcalcetide hydrochloride) for secondary hyperparathyroidism - Clinical efficacy of etelcalcetide hydrochloride for secondary hyperparathyroidism

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000027408

Enrollment

Registered

2017-05-19

Start date

2017-05-26

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

End-stage renal disease

Interventions

5 micro gram of etelcalcetide hydrochloride is intravenously injected after each dialysis. The dose of etelcalcetide hydrochloride is appropriately increased or decreased depending on levels of intact

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Maintenance hemodialysis patients with Intact PTH> 240 pg / mL and corrected serum calcium 8.4 mg / dL or more

Exclusion criteria

Exclusion criteria: Hypocalcemic patients with corrected serum calcium level <8.4 mg / dL

Design outcomes

Primary

Measure	Time frame
Parathyroid hormone (PTH) value, corrected calcium value, and phosphorus value every 3 months after administration of ethelcarcitrate hydrochloride	—

Secondary

Measure	Time frame
Bone metabolism marker, bone density, and parathyroid volume every 6 months after the administration of ethelcarcitrate hydrochloride	—

Countries

Japan

Contacts

Public ContactSatoshi Kurihara

Saitama Tsukinomori Clinic Department of Nephrology

kurihara@k-naika-cl.jp048-792-1811

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026